| 发明名称 | Combination treatment of cancer with cetuximab and tetrac | ||
| 摘要 | Provided herein are compositions and methods for treating cancer by increasing the inhibitory effect of cetuximab on HIF1α expression by administering cetuximab in combination with anti-angiogenic thyroid hormone analogs such as tetrac or triac. | ||
| 申请公布号 | US9180107(B2) | 申请公布日期 | 2015.11.10 |
| 申请号 | US201012751375 | 申请日期 | 2010.03.31 |
| 申请人 | NANOPHARMACEUTICALS LLC | 发明人 | Lin Hung-Yun;Davis Faith B.;Davis Paul J.;Mousa Shaker A. |
| 分类号 | A01N59/22;A61K9/14;A61K9/16;A61K9/50;A61K39/00;A61K39/395;C07K16/00;C12P21/08;A61K31/192;A61K45/06;A61K47/48 | 主分类号 | A01N59/22 |
| 代理机构 | Schmeiser, Olsen & Watts, LLP | 代理人 | Schmeiser, Olsen & Watts, LLP |
| 主权项 | 1. A pharmaceutical composition comprising a combination of cetuximab and an anti-angiogenic thyroid hormone analog selected from the group consisting of tetrac (tetraiodothyroacetic acid), triac (triiodothyroacetic acid) and a combination thereof, wherein the thyroid hormone analog is conjugated via a covalent bond to a polymer, wherein the cetuximab is at least one of encapsulated within said polymer, conjugated via a covalent bond to the polymer and a combination thereof. | ||
| 地址 | Rensselaer NY US | ||